| Joshua David Sussman, MD | |
|
9400 Rosecrans Ave, Bellflower, CA 90706-2246 | |
| (562) 461-3000 | |
| Not Available |
| Full Name | Joshua David Sussman |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 23 Years |
| Location | 9400 Rosecrans Ave, Bellflower, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417005356 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | A82076 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern California Permanente Medical Group | 6002729175 | 7951 |
News Archive
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain.
"Treating a yellow fever patient is reliant on having the right diagnosis. This is dependent on having the necessary laboratory capacity to quickly identify the disease," says Dr Pierre Formenty, an expert in haemorrhagic fevers at WHO and Manager of the Emerging Dangerous Pathogens Laboratory Network.
Australia's medicines regulator, the Therapeutic Goods Administration (TGA) is considering a recommendation by its expert committee, the Australian Drug Evaluation Committee (ADEC), to conditionally approve an application by Roche Products Pty Limited to extend the registration of the breast cancer drug Herceptin (trastuzumab) for use in HER2 positive localised breast cancer in addition to chemotherapy.
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the closing of an additional and partial exercise of the over-allotment option granted to the underwriters.
Two researchers at Saint Louis University's division of rheumatology in the department of internal medicine have been awarded a $1.8 million NIH grant to study the physiological and biochemical functions in lupus, an autoimmune disease, and develop possible new medications for its treatment.
› Verified 7 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain.
"Treating a yellow fever patient is reliant on having the right diagnosis. This is dependent on having the necessary laboratory capacity to quickly identify the disease," says Dr Pierre Formenty, an expert in haemorrhagic fevers at WHO and Manager of the Emerging Dangerous Pathogens Laboratory Network.
Australia's medicines regulator, the Therapeutic Goods Administration (TGA) is considering a recommendation by its expert committee, the Australian Drug Evaluation Committee (ADEC), to conditionally approve an application by Roche Products Pty Limited to extend the registration of the breast cancer drug Herceptin (trastuzumab) for use in HER2 positive localised breast cancer in addition to chemotherapy.
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the closing of an additional and partial exercise of the over-allotment option granted to the underwriters.
Two researchers at Saint Louis University's division of rheumatology in the department of internal medicine have been awarded a $1.8 million NIH grant to study the physiological and biochemical functions in lupus, an autoimmune disease, and develop possible new medications for its treatment.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua David Sussman, MD 9400 Rosecrans Ave, Bellflower, CA 90706-2246 Ph: (562) 461-3000 | Joshua David Sussman, MD 9400 Rosecrans Ave, Bellflower, CA 90706-2246 Ph: (562) 461-3000 |
News Archive
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain.
"Treating a yellow fever patient is reliant on having the right diagnosis. This is dependent on having the necessary laboratory capacity to quickly identify the disease," says Dr Pierre Formenty, an expert in haemorrhagic fevers at WHO and Manager of the Emerging Dangerous Pathogens Laboratory Network.
Australia's medicines regulator, the Therapeutic Goods Administration (TGA) is considering a recommendation by its expert committee, the Australian Drug Evaluation Committee (ADEC), to conditionally approve an application by Roche Products Pty Limited to extend the registration of the breast cancer drug Herceptin (trastuzumab) for use in HER2 positive localised breast cancer in addition to chemotherapy.
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the closing of an additional and partial exercise of the over-allotment option granted to the underwriters.
Two researchers at Saint Louis University's division of rheumatology in the department of internal medicine have been awarded a $1.8 million NIH grant to study the physiological and biochemical functions in lupus, an autoimmune disease, and develop possible new medications for its treatment.
› Verified 7 days ago
Elise H. Lee, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000 | |
Charn-jiuan Huang, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000 | |
Paul S. Hwang, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000 | |
Jan J. Li, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000 | |
David A. Sweeney, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000 | |
Christine Phan, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000 |